KEYNOTE-158 went on to evaluate pembrolizumab monotherapy in 101 metastatic vulvar cancer patients with prior treatment failure and demonstrated an objective response rate of 10.9% regardless of tumor PD-L1 expression with a median duration of response of 20.4 months in treatment responders [59]. This evidence concerns the gene CD274 and vulva cancer.